Exogenous CTS (digoxin, digitoxin) is intended for patients with heart failure with reduced ejection fraction and AF with rapid ventricular rate, especially if previously approved therapy (diuretics, angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers, -blockers, and aldosterone receptor antagonists) fails (162–167). This evidence concerns the gene ACE and heart failure.